Showing 1 - 5 results of 5 for search 'Gloria Iacoboni', query time: 0.02s Refine Results
  1. 1
    Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example

    Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example by Gloria Iacoboni, María Pérez Raya

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    WCN24-2513 TRANSIENT ACUTE KIDNEY INJURY AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

    WCN24-2513 TRANSIENT ACUTE KIDNEY INJURY AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES by María José Soler Romeo, Gloria Iacoboni, Sheila Bermejo, Cecilia Carpio, Mónica Bolufer, Clara García-Carro, Mario Sánchez, Carla Alonso-Martínez, Pere Barba, Ander Vergara Arana

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders

    Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders by Ángel Serna, Víctor Navarro, Moraima Jiménez, Josu Iraola-Truchuelo, Marc Bosch, Cristina García, Anna Falcó, Adaia Albasanz, Isabel Ruiz-Camps, Cristina Andrés, Andrés Antón, Juliana Esperalba, Ainara Ferrero, Tomás García, Cecilia Carpio, Marta Crespo, Gloria Iacoboni, Ana Marín-Niebla, Francesc Bosch, Pau Abrisqueta

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma

    Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell ly... by Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

    Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment by Gloria Iacoboni, Víctor Navarro, Pierre Sesques, Kai Rejeski, Mariana Bastos-Oreiro, Fabio Serpenti, Ana Africa Martin Lopez, Josu Iraola-Truchuelo, Javier Delgado, Ariadna Perez, Manuel Guerreiro, Ana Carolina Caballero, Nuria Martinez-Cibrian, Hugo Luzardo Henriquez, Jose Maria Sanchez Pina, Juan-Manuel Sancho, Hervé Ghesquieres, Alberto Mussetti, Lucia Lopez Corral, Rafael Hernani, Juan Luis Reguera, Anna Sureda, Francesc Bosch, Alejandro Martin Garcia-Sancho, Mi Kwon, Marion Subklewe, Andrea Kuhnl, Emmanuel Bachy, Pere Barba, Guillermo Villacampa, Pau Abrisqueta

    Published 2024-10-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: